Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNXNASDAQ:AYTUNYSE:IBIONASDAQ:INDP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNXAthenex$0.95$0.20▼$23.80$1.76M1.36194,316 shs1.88 million shsAYTUAytu BioPharma$2.10-0.9%$1.69$0.95▼$2.96$18.86M0.05371,119 shs57,998 shsIBIOiBio$0.76+6.3%$0.85$0.64▼$6.89$12.47M0.96837,432 shs2.02 million shsINDPIndaptus Therapeutics$11.64+2,435.4%$0.62$7.56▼$66.64$6.64M1.3262,062 shs41,474 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNXAthenex0.00%0.00%0.00%0.00%0.00%AYTUAytu BioPharma0.00%+5.00%+17.98%+75.00%-28.08%IBIOiBio0.00%-2.08%-1.63%-81.22%-64.22%INDPIndaptus Therapeutics0.00%+4,209.51%+3,358.11%+2,016.75%+449.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNXAthenexN/AN/AN/AN/AN/AN/AN/AN/AAYTUAytu BioPharma0.7375 of 5 stars0.02.00.03.42.10.00.6IBIOiBio1.6184 of 5 stars3.50.00.00.01.80.00.6INDPIndaptus Therapeutics1.2313 of 5 stars1.54.00.00.01.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNXAthenex 0.00N/AN/AN/AAYTUAytu BioPharma 0.00N/AN/AN/AIBIOiBio 3.00Buy$4.30469.54% UpsideINDPIndaptus Therapeutics 3.00Buy$8.50-26.98% DownsideCurrent Analyst Ratings BreakdownLatest ATNX, IBIO, INDP, and AYTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.005/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNXAthenex$102.82M0.00N/AN/A($3.07) per share0.00AYTUAytu BioPharma$81M0.23N/AN/A$4.64 per share0.45IBIOiBio$375K33.26N/AN/A$1.41 per share0.54INDPIndaptus TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNXAthenex-$103.43M-$15.88N/AN/AN/A-86.31%-727.79%-44.44%N/AAYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A2.37%3.51%0.91%N/AIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/AINDPIndaptus Therapeutics-$15.02M-$1.49N/AN/AN/AN/A-333.02%-216.36%8/11/2025 (Estimated)Latest ATNX, IBIO, INDP, and AYTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025AYTUAytu BioPharma-$0.17$0.20+$0.37$0.21$13.74 million$18.45 million5/14/2025Q1 2025INDPIndaptus Therapeutics-$0.41-$0.32+$0.09-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNXAthenexN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNXAthenex3.081.090.72AYTUAytu BioPharma0.271.030.87IBIOiBio0.051.761.76INDPIndaptus TherapeuticsN/A1.901.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNXAthenex30.48%AYTUAytu BioPharma33.49%IBIOiBio7.90%INDPIndaptus Therapeutics7.06%Insider OwnershipCompanyInsider OwnershipATNXAthenex9.20%AYTUAytu BioPharma3.60%IBIOiBio0.58%INDPIndaptus Therapeutics20.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNXAthenex6528.66 million7.87 millionOptionableAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableIBIOiBio10016.52 million9.82 millionN/AINDPIndaptus Therapeutics6570,000453,000Not OptionableATNX, IBIO, INDP, and AYTU HeadlinesRecent News About These CompaniesIndaptus Therapeutics Announces Reverse Stock Split - FinanzNachrichten.deJune 26, 2025 | finanznachrichten.deIndaptus Therapeutics, Inc. Announces One-for-Twenty-Eight Reverse Stock Split to Enhance Nasdaq Compliance and Attract InvestorsJune 26, 2025 | nasdaq.comIndaptus Therapeutics Announces Reverse Stock SplitJune 25, 2025 | globenewswire.comIndaptus Therapeutics, Inc. Secures $2.3 Million Through Convertible Promissory Notes and Warrants in Funding RoundJune 13, 2025 | quiverquant.comQIndaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and WarrantsJune 13, 2025 | globenewswire.comIndaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor TislelizumabJune 2, 2025 | globenewswire.comIndaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comIndaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development SummitMay 8, 2025 | globenewswire.comIndaptus Therapeutics, Inc. Common StockMarch 30, 2025 | fxempire.comFIndaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 SummitMarch 25, 2025 | globenewswire.comIndaptus Therapeutics reports new data on Phase 1 trial of Decoy20March 21, 2025 | markets.businessinsider.comIndaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20March 20, 2025 | globenewswire.comIndaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor TislelizumabMarch 18, 2025 | globenewswire.comIndaptus Therapeutics reports FY24 EPS ($1.61) vs ($1.83) last yearMarch 13, 2025 | markets.businessinsider.comIndaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate UpdateMarch 13, 2025 | globenewswire.comRegistration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025March 12, 2025 | globenewswire.comIndaptus Therapeutics expands patent portfolio in China, Japan, IsraelMarch 4, 2025 | markets.businessinsider.comIndaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer TreatmentsMarch 4, 2025 | globenewswire.comIndaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer SummitFebruary 25, 2025 | markets.businessinsider.comIndaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer SummitFebruary 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATNX, IBIO, INDP, and AYTU Company DescriptionsAthenex NASDAQ:ATNXAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.Aytu BioPharma NASDAQ:AYTU$2.10 -0.02 (-0.94%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.15 +0.05 (+2.38%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.iBio NYSE:IBIO$0.76 +0.05 (+6.34%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.73 -0.02 (-3.18%) As of 04:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Indaptus Therapeutics NASDAQ:INDP$11.64 +11.18 (+2,435.40%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$10.99 -0.65 (-5.58%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
